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Abstract Glucocorticoids (GCs) are steroid hormones that
have inflammatory and immunosuppressive effects on a wide
variety of cells. They are used as therapy for inflammatory
disease and as a common agent against edema. The blood
brain barrier (BBB), comprising microvascular endothelial
cells, serves as a permeability screen between the blood and
the brain. As such, it maintains homeostasis of the central
nervous system (CNS). In many CNS disorders, BBB integ-
rity is compromised. GC treatment has been demonstrated to
improve the tightness of the BBB. The responses and effects
of GCs are mediated by the ubiquitous GC receptor (GR).
Ligand-bound GR recognizes and binds to the GC response
element located within the promoter region of target genes.
Transactivation of certain target genes leads to improved
barrier properties of endothelial cells. In this review, we deal
with the role of GCs in endothelial cell barrier function. First,
we describe the mechanisms of GC action at the molecular
level. Next, we discuss the regulation of the BBB by GCs,
with emphasis on genes targeted by GCs such as occludin,
claudins and VE-cadherin. Finally, we present currently avail-
able GC therapeutic strategies and their limitations.
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Introduction
Glucocorticoids (GCs) belong to a class of steroid hormones
that bind to GC receptors (GRs), which, once activated as a
complex, upregulate the expression of anti-inflammatory
proteins in the nucleus and repress the expression of proin-
flammatory proteins in the cytosol (Rhen and Cidlowski
2005). GCs are the first-choice therapy for inflammatory
disease and a common anti-edematous agent. Administration
of GCs is employed as a novel treatment strategy for several
central nervous system (CNS) diseases such as brain tumors,
brain edema and multiple sclerosis (MS).
The neurovascular unit of the CNS is made up of micro-
vascular endothelial cells that seal the paracellular spaces
between the blood and brain and, thus, are often referred to
as the blood brain barrier (BBB), together with circulating
blood components, pericytes, astrocytes and neurons
(Neuwelt et al. 2008). In many disorders of the CNS, the
integrity of the BBB is compromised. Since GCs are found
to improve barrier properties, they are often used for the
therapy of CNS disorders that involve the BBB. GC treatment
has demonstrated a tightening of the BBB in the murine
microvascular brain endothelial cells, cEND (Förster et al.
2005, 2006).
Mechanisms of GC action at the molecular level
GCs act on a wide variety of cell types leading to many
different physiological and pathological responses and sys-
temic effects. These responses and effects are mostly attribut-
able to the ubiquitous nature of the GR. The action of GCs
begins when the GC crosses the cell membrane and binds to a
GR (Fig. 1). GRs are located in the cytoplasm and belong to
the thyroid/retinoic acid receptor superfamily, which is com-
posed of ligand-dependent transcription factors (Evans 1988;
Tsai and O’Malley 1995). Within the cytoplasm, GRs are
maintained in an inactive state by being bound to heat shock
proteins (hsps) to prevent them from moving into the nucleus
(Wikstrom et al. 1986; Picard et al. 1988; Dao-Phan et al.
1997). Once the GC binds to a GR, the hsps dissociate and the
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GC-GR complex then translocates into the nucleus in which it
dimerizes with a secondGC-GR complex (Dittmar et al. 1997;
Hawle et al. 2006).
The zinc-finger domains of the GR can bind to specific DNA
sequences, i.e., GC-responsive elements (GREs), in the 5′ pro-
moter region. TheGR can then activate transcription in a process
termed GR transactivation (Beato 1989; Schaaf and Cidlowski
2003; Harke et al. 2008). However, if the region contains a
negative GRE, transcription is repressed (Sakai et al. 1988;
Drouin et al. 1989; Nakai et al. 1991; Subramaniam et al. 1998).
The inflammatory and immunosuppressive effects of GCs
rely on several molecular mechanisms that include (1) direct
effects on gene expression by the binding of GRs to GREs; (2)
indirect effects on gene expression by the interaction of GRs
with other transcription factors; (3) GR-mediated effects on
second messenger cascades, i.e., the P13K-Akt-eNOS path-
way (Rhen and Cidlowski 2005).
Glucocorticoid receptor
GRs mediate the biological effects of GCs (Beato 1989). They
are a type II steroid receptor and transcription factor and alter
the expression of target genes involved in multiple cellular
processes such as immune function, inflammation and cell
death (Schaaf and Cidlowski 2003). As a type II receptor, GR
is expressed in almost all tissues and cells. It has a binding
affinity for cortisol of approximately 30 nM, which is within
the physiological range of serum cortisol values (Umland et al.
2002). GR is expressed in two isoforms, namely, GRα and
GRβ, which share identical N-termini and are distinguished
only by their unique C-terminal ligand-binding domain (Lewis-
Tuffin and Cidlowski 2006). GRα binds cortisol, DNA and
other transcription factors, thereby modifying the transcription-
al activity of target genes (Lu and Cidlowski 2004). On the
other hand, GRβ does not bind any ligands and fails to activate
transcription, although it forms homodimers that bind DNA.
Relative levels of these two GR isoforms in a cell influence the
sensitivity of the cell to GC. Higher levels of GRβ lead to GC
resistance (Pujols et al. 2001).
Blood brain barrier
The BBB is a diffusion barrier essential for the normal func-
tioning of the CNS (Ballabh et al. 2004). It is composed of
highly specialized endothelial cells, which, together with cir-
culating blood components, pericytes, astrocytes, microglia,
neurons and basement membrane form a neurovascular unit
(Neuwelt et al. 2008). The capillary endothelial cells that
make up the BBB are formed by tight junctions (TJs) that seal
paracellular spaces between the endothelial cells thereby
restricting paracellular permeability (Wolburg and Lippoldt
2002; Förster 2008). The integral membrane proteins claudin,
Fig. 1 Mechanisms of
glucocorticoid (GC) action. GC
crosses the cell membrane and
binds to the glucocorticoid
receptor (GR) in the cytoplasm.
GRs are kept in an inactive state
and prevented from moving into
the nucleus by heat shock proteins
(HSP). Upon binding of a GC to a
GR, the HSP dissociates and the
GC-GR complex moves to the
nucleus via a nuclear pore (NP).
The complex then binds to GC-
responsive elements (GRE) in the
5′ promoter region of DNA.
Transcription is then activated.
However, if the region contains a
negative GRE, transcription is
repressed
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occludin and junction adhesion molecules make up the TJs,
alongside a number of cytoplasmic accessory proteins includ-
ing zonula occludens (ZO)-1, ZO-2, ZO-3 and cingulin
(Ballabh et al. 2004). Junctional protein disintegration plays
a major role in BBB breakdown during MS, meningitis, or
brain neoplasm (Förster et al. 2008).
Regulation of BBB by GCs
Many factors regulate the BBB. Changes in the expression of
junctional proteins in the endothelial cells through metabolic
or cellular mediators play a role in this regulation leading to
dynamic changes in BBB properties (Madra et al. 1986;
Madara 1988; Schneeberger and Lynch 1992; Citi 1993;
Leach et al. 2000; Schweingruber et al. 2011). However,
GCs are also important regulators of BBB properties together
with other factors such as growth factors or calcium.
Treatment of tumor-induced brain edema by GC reduces
microvessel permeability. Several studies have demonstrated
the molecular mechanisms behind this. For instance, treatment
of epithelial cells with dexamethasone, a synthetic GC, influ-
ences the differentiation of TJ proteins (Buse et al. 1995). It
increases transendothelial electrical resistance (TER) and ZO-
1 expression (Singer et al. 1994). In addition, dexamethasone
has also been found to influence TJ expression leading to a
reduction of permeability in rat (Romero et al. 2003; Calabria
et al. 2006), murine (Förster et al. 2005; Weidenfeller et al.
2005), porcine (Hoheisel et al. 1998; Lohmann et al. 2002)
and human (Weksler et al. 2005; Förster 2008) endothelial
cells. In the advent of a neuroinflammatory response,
cell adhesion molecules such as intercellular adhesion
molecule-1 (ICAM-1) and vascular cell adhesion molecule-1
(VCAM-1) become upregulated on endothelial cells facilitat-
ing lymphocyte extravasation across the BBB (Engelhardt
2006). GCs inhibit BBB disruption thereby reducing leuko-
cyte infiltration into the CNS (Paul and Bolton 1995).
Genes of vascular endothelium targeted by GCs
Occludin
The TJ protein occludin was the first integral protein to be
identified, initially in the chicken (Furuse et al. 1993) and then
in mammals (Anko-Akatsuka et al. 1996). It is composed of
four transmembrane domains, two extracellular loops of sim-
ilar size, three cytoplasmic domains, a short cytoplasmic N-
terminus and a long C-terminus (Gonzalez-Mariscal et al.
2003). Although occludin localizes at the TJs, it cannot form
TJ strands by itself (Furuse et al. 1996). In addition, the
formation of an effective diffusion barrier and epithelial cell
polarization are not prevented by the disruption of both
occludin alleles in embryonic stem cells (Saitou et al. 1998).
Moreover, occludin knock-out mice display well-developed
TJs (Saitou et al. 2000).
Nonetheless, several lines of evidence show that occludin
plays an important role at TJs. It contributes to the electrical
barrier function of TJs and possibly to the formation of aque-
ous pores within TJ strands (McCarthy et al. 1996). Moreover,
the N-terminal half of occludin has demonstrated its important
role for TJ assembly and barrier function maintenance
(Bamforth et al. 1999). Overexpression of occludin increases
TER in mammalian epithelial cells (Balda et al. 1996).
Originally hydrocortisone (HC) was reported to reinforce
blood–brain properties in a serum-free cell culture system of
cultured porcine cerebral capillary endothelial cells (Hoheisel
et al. 1998). Next, GCs were shown to induce a more differ-
entiated BBB phenotype through the modification of TJ struc-
ture in cultured rat brain endothelial cells (Romero et al.
2003). Then, the tightening effects of GC treatment was
demonstrated in the murine cerebrovascular endothelial cell
line cEND (Förster et al. 2005, 2006) and in human hDMEC/
D3 cells (Förster 2008). Study of GC effects on the improve-
ment of BBB properties in a murine in vitro system was, for
the first time, able to identify occludin as a direct target for GC
(Förster et al. 2005). GCs were shown to induce occludin
expression (Fig. 2); this was dependent on the GR. A GC
response element (GRE) was identified as a GR-binding site
within the occludin promoter. This indicated that
transactivation of occludin occurred through the GRE
(Harke et al. 2008). Moreover, GC treatment antagonized
the effects of tumor necrosis factor-α (TNF-α) on occludin
expression in endothelial cell lines (Silwedel and Förster
2006).
Claudins
Despite disruption of both alleles of the occludin gene in
embryonic stem (ES) cells, well-developed TJs were found
between adjacent epithelial cells. This led to the conclusion
that occludin was not necessarily required for TJ formation
itself and indicated that other unidentified TJ integral mem-
brane protein(s) could form strand structures without occludin
(Saitou et al. 1998). Concomitantly, peptide sequencing led to
the discovery of two putative TJ integral proteins that were
Fig. 2 Genes of the microvascular endothelium are targeted by gluco-
corticoids (GC). GC treatment induces the expression of tight junction
proteins occludin and claudin-5 and the adherens junction protein vascu-
lar endothelium cadherin (VE-Cadherin)
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subsequently named claudin 1 and 2 (Furuse et al. 1998). So
far, 24 members of the claudin family have been identified
(Tsukita et al. 2001). These proteins show sequence similarity
to each other and also bear four putative transmembrane
domains but do not show any sequence similarity to occludin
(Furuse et al. 1998).
Endothelial cells of the BBB express claudin-1, -3, -5
and -12 (Wolburg and Lippoldt 2002; Krause et al. 2008).
Claudin-5 plays an important role in the maintenance of BBB
function. Mice that are claudin-5-deficient are born alive but
die within a day after birth with no morphological abnormal-
ities. This can be attributed to the integrity of the BBB of these
mice being severely decreased, since it is selectively perme-
able to molecules with a size of < 800 Da (Nitta et al. 2003).
The murine claudin-5 promoter has been cloned and char-
acterized (Burek and Förster 2009). Putative GREs in the
promoter sequence have been identified. An increase in
claudin-5 promoter activity and mRNA expression occurs after
dexamethasone treatment. In addition, increased claudin-5
mRNA and protein expression resulting in higher TER of the
endothelial cells has been observed after GC treatment (Fig. 2;
Förster et al. 2006; Felinski et al. 2008; Förster 2008;
Sadowska et al. 2010). Claudin-5 is also regulated by estrogens
on promoter, mRNA and protein levels (Burek et al. 2010).
Vascular endothelium cadherin
Together with TJs, adherens junctions (AJs) maintain the
restrictiveness of the barrier in endothelial cells (Fig. 2). The
most important AJ protein is vascular endothelial cadherin
(VE-cadherin), which is exclusively expressed in vessels in
which it regulates Ca2+-mediated adhesion (Dejana et al.
1999; Dejana 2004; Gumbiner 2005; Gavard 2009).
Deletion of VE-cadherin in mice produces massive vascular
effects leading to early embryonic death. On the other hand,
loss of its function provokes a hyperpermeability in adults
(Carmeliet et al. 1999; Crosby et al. 2005).
Treatment of endothelial cells with dexamethasone in-
creases VE-cadherin protein levels. Transcriptional activation
of the VE-cadherin promoter by dexamethasone, however,
does not point to direct GC-mediated VE-cadherin gene in-
duction (Blecharz et al. 2008). Although TJs and AJs are
formed by different molecules, they are functionally and
structurally linked. VE-cadherin at AJs upregulates the gene
encoding claudin-5 via the release of the inhibitory activity of
the forkhead box factor FoxO1 and the Tcf-4-beta-catenin
transcriptional repressor complex (Taddei et al. 2008).
GC therapeutic strategies and their limitations
The BBB is compromised in many CNS disorders. To function
normally, the CNS needs to maintain its microenvironment;
this is performed by the BBB via its regulation of molecule
transport between the blood and the brain. Since TJ and AJ
proteins contribute to endothelial cell barrier restrictiveness, the
effects of GCs toward upregulation in the expression of these
proteins leading to a tightening of the barrier are used to advan-
tage for therapeutic purposes against many diseases of the CNS
including MS, human immunodeficiency (HIV)-1-associated
dementia, CNS vasculitides, stroke, Alzheimer’s disease and
cerebral malaria (Fig. 3).
Multiple sclerosis
MS, a neuroinflammatory disorder characterized by infiltrat-
ing autoreactive T-cells in the CNS, is the most prevalent
chronic autoimmune disease in the western world
(Noseworthy et al. 2000; Sospedra and Martin 2005). Most
patients suffer from a relapsing-remitting form of the disease
whose exacerbations are initiated by BBB breakdown and
subsequent tissue damage. Because of the infiltration of acti-
vated immune effector cells into the brain, an inflammatory
cascade involving leukocytes and humoral components arises
(Steinman 2001; Engelhardt 2006). Even though GC treat-
ment has little effect on the long-term prognosis of MS, high
dosage GC therapy is an approved first line treatment for MS
relapses (Milligan et al. 1987; Reichhardt 2004).
For more than 70 years, experimental autoimmune enceph-
alomyelitis (EAE) has served as a model for MS (Gold et al.
2006). In using this model, together with studies of MS
patient, multiple beneficial effects of GC treatment have been
established. GCs have anti-inflammatory and immunosup-
pressive activities and can induce apoptosis. Their induction
of apoptosis in T-cells leads to the activation of caspases,
Fig. 3 Most diseases and disorders of the central nervous system (CNS)
involve the disruption of the blood brain barrier (BBB), decreasing its
permeability. Administration of glucocorticoids (GC) induces the expres-
sion of adherens junctions (AJ ) and tight junctions (TJ ) leading to
increased barrier tightness
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release of cathepsin B from lysosomes and increased H2O2
levels (Screpanti et al. 1989; Gold et al. 2006). GCs inhibit the
disruption of the BBB and hence reduce leukocyte infiltration
into the CNS (Paul and Bolton 1995). Direct effects of GCs on
the BBB have been demonstrated in vitro (Tischner and
Reichardt 2007). For instance, in cultured brain endothelial
cells, dexamethasone induces pore reduction and F-actin con-
centration on the cell periphery and increases ZO-1 and
occludin expression (Romero et al. 2003; Förster et al. 2005,
2006). In addition, the administration of dexamethasone and
HC preserves the functional integrity of TJs and AJs under
pro-inflammatory conditions by maintaining the levels of TJ
components such as occludin, claudin-1, claudin-12, ZO-1
and VE-cadherin. However, dexamethasone effects on
claudin-5 are negligible (Förster et al. 2007; Blecharz et al.
2008).
ICAM-1 and VCAM-1 are expressed by endothelial cells
of the BBB in response to pro-inflammatory cytokines such as
interferon-γ and TNFα. Treatment with GCs reduces the
expression of these adhesion molecules (Gelati et al. 2000;
Sloka and Stefanelli 2005). Accordingly, integrins on enceph-
alitogenic T-cells interact with these adhesion molecules,
which are required for the extravasation of additional effector
T-cells into the CNS (Engelhardt 2006). Production of
interleukin-8 by monocytes, which also contributes to BBB
disruption through leukocyte recruitment to the CNS, is also
decreased in MS patients following GC treatment (Mirowska-
Guzel et al. 2006).
The opening of the BBB as promoted by cytokines has
been shown to occur because of TJ protein degradation and
decreased synthesis. This results in compromised junctional
integrity (Harkness et al. 2000; Chang and Werb 2001;
Silwedel and Förster 2006; Yang et al. 2007). TJ degradation
in neuroinflammatory conditions such as MS results from the
effects of matrix metalloproteinases (MMPs) in BBB disrup-
tion. MMP-9 (gelatinase B) is increased in cerebrospinal fluid
levels inMS patients. An important regulator ofMMP activity
is via binding to a family of homologous proteins referred to
as tissue inhibitors of MMPs (TIMPs; Brew et al. 2000). All
four known TIMPS have been demonstrated in the BBB
endothelium (Hartmann et al. 2009). In MS patients, TIMP
levels are reduced in comparison with controls. This suggests
an imbalance in MMP-9/TIMP ratios (Avolio et al. 2005). GC
treatment reduces levels of MMP-9, based on the GC-
mediated activation of the TIMP-1 gene and has been shown
to lead to an upregulation of TIMP-1 in the murine cerebral
vascular endothelial cell line, cEND (Förster et al. 2007). In
contrast, HC has been revealed selectively to upregulate
TIMP-3, whereas TIMP-1, TIMP-2 and TIMP-4 are down-
regulated at the mRNA-level in endothelial cells of cerebral
capilllaries in porcine brain. This effect can be completely
reversed by the GR inhibitor mifepristone. The application of
HC leads to a strong enrichment of TIMP-3 in the endothelial
cell membrane (Hartmann et al. 2009). Moreover, the down-
regulation of claudin-5 and occludin protein andmRNA levels
occurs together with MMP-9 expression upregulation after
incubation of the murine microvascular endothelial cells,
cEND, with serum from MS patients (Blecharz et al. 2010).
Ischemic stroke
GCs are known to stabilize the BBB in many inflammatory
CNS disorders and even to decrease edema formation.
However, in some other cases of CNS disease, it tends to
aggravate the condition rather than diminish the negative ef-
fects. For instance, when GC treatment is applied to acute
ischemic stroke, it is ineffective or even harmful (Saul et al.
1981; Norris and Hachinski 1986; De Reuck et al. 1988;
Kumar et al. 1989; Norris 2004; Poungvarin 2004; Roberts
et al. 2004). This is attributed to GC insensitivity at the hypoxic
BBB. In the cultured murine brain microvascular endothelial
cells, cEND, O2/glucose deprivation reduces TJ protein expres-
sion and TER. Treatment with dexamethasone fails to reverse
these effects during hypoxia. Apparently, proteasome-
dependent degradation of the GR impairs GR transactivation,
in turn preventing physiological GC activity. Inhibition of the
proteasome with Bortezomib, however, fully restores the BBB
stabilizing properties of GC during O2/glucose deprivation
(Kleinschnitz et al. 2011).
Effects of ubiquitination on GC response during hypoxia
Post-translational modifications of the GR include phosphory-
lation under various conditions by cyclin-dependent kinases
and mitogen-activated protein kinases (MAPKs), sumoylation
and ubiquitination (Tischner and Reichardt 2007).
Ubiquitination determines protein longevity in cells and plays
major roles in signaling (Ernst and Sidhu 2013) being a form of
post-translational modification that targets a protein for rapid
degradation by the proteasome (Meller 2009). Excessive
proteosomal GR degradation in response to long-term GC
exposure has been shown to lead to GC insensitivity in the
vascular endothelium (Förster et al. 2006). An endothelial GR
protein has been identified as a potential proteasome substrate
after hypoxia (Kleinschnitz et al. 2011).
GC responses are dependent on the post-translational mod-
ification and degradation of GR to which GC binds to form a
complex and begin its activity. The ubiquitin-proteosome sys-
tem plays a major part in this modification and degradation.
Degradation of the proteasome by nuclear receptors is a phys-
iological process necessary to terminate transcriptional activity
after ligand binding. It can, however, also restrict transcription-
al signaling by steroids under certain pathophysiological con-
ditions thereby compromising steroid function (Meller 2009).
In an in vitro BBB model subjected to O2/glucose deprivation,
degradation of the GR in a proteasome-dependent manner
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leading to impaired GC sensitivity has been observed. When
the proteasome is inhibited, the responsivity of the BBB to GC
during hypoxia is restored. When proteosomal inhibition is
combined with GC treatment, edema formation is attenuated,
as are neurological deficits after transient middle cerebral artery
occlusion (tMCAO) in mice, which is an established in vivo
model of hypoxic BBB damage (Kleinschnitz et al. 2011).
In addition, studies have shown that cell-death-mediating
proteins are rapidly degraded by the ubiquitin-proteosome sys-
tem. For instance, some pro-apoptotic proteins such as Bim and
Puma have been identified as direct GR targets (Erlacher et al.
2005; Wang et al. 2006). Therefore, a better understanding of
the mechanisms by which this occurs might prove to be useful
for therapy during ischemia and other brain injuries.
Action of GC-based combination therapy with proteosomal
inhibitors against edema
Although GCs diminish edema formation in neuroinflammatory
diseases such as acute MS lesions and in certain brain tumors,
they are ineffective or even harmful in brain disorders such as
acute ischemic stroke or traumatic brain injury (TBI; Kumar et al.
1989). Stroke and other forms of ischemic brain injury result in
excessive edema formation in the brain leading to morbidity and
mortality (Kahle et al. 2009). Therefore, the finding that GCs can
diminish edema in some neuroinflammatory diseases but not in
ischemia or TBI is unfortunate.
Degradation of GR occurs during O2/glucose deprivation
in cEND cells and in the tMCAO model of stroke
(Kleinschnitz et al. 2011). However, the use of pharmacolog-
ical proteasome inhibitors is able to prevent it. GR
transactivation by GC binding has been found to be main-
tained through the overexpression of a GR mutant resistant to
proteasomal degradation (GR-K426A mutant; Wallace and
Cidlowski 2001). These findings have led to the development
of a combined treatment strategy by using GCs combinedwith
inhibitors of the proteasome. This novel therapy effectively
and significantly reduces edema formation. Furthermore, it
significantly ameliorates neurological performance in mouse
models of stroke and TBI (Kleinschnitz et al. 2011).
Concluding remarks
The ability of GCs to improve barrier properties and induce the
expression of TJ proteins occludin and claudin-5 and AJ pro-
tein VE-cadherin demonstrates their positive effects toward the
BBB. Even though high dosage administration of GCs has
been found to be ineffective or even harmful in brain disorders
such stroke or TBI, novel strategies such as combination ther-
apy of GCs and proteasome inhibitors have proven effective in
the prevention of BBB disruption, edema formation and neu-
ronal damage upon brain injury both in vivo and in vitro.
Therefore, further studies concerning the GR-mediated regula-
tion of BBB permeability are needed for the development of
more and better therapeutic strategies with GCs.
Currently, the establishment of an in vitro human stroke
model based on human brain capillary endothelial cells in our
working group together with cooperating partners is under-
way. The model is in the process of being tested, verified and
strengthened for use in various experimental procedures.
Once this model is established, it should prove highly benefi-
cial in medical and biological research.
Open Access This article is distributed under the terms of the Creative
Commons Attribution License, which permits any use, distribution and
reproduction in any medium, provided the original author(s) and the
source are credited.
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